

Global Immunotherapy for Neuroblastoma Market Growth (Status and Outlook) 2023-2029

<https://marketpublishers.com/r/GEC8E5EF9F48EN.html>

Date: June 2023

Pages: 88

Price: US\$ 3,660.00 (Single User License)

ID: GEC8E5EF9F48EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Immunotherapy for Neuroblastoma market size is projected to grow from US\$ 44 million in 2022 to US\$ 61 million in 2029; it is expected to grow at a CAGR of 4.8% from 2023 to 2029.

United States market for Immunotherapy for Neuroblastoma is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Immunotherapy for Neuroblastoma is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Immunotherapy for Neuroblastoma is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Immunotherapy for Neuroblastoma players cover United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals and Teva Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread

beyond its initial location and the risk of the tumor growing or spreading in the future.

LPI (LP Information)' newest research report, the “Immunotherapy for Neuroblastoma Industry Forecast” looks at past sales and reviews total world Immunotherapy for Neuroblastoma sales in 2022, providing a comprehensive analysis by region and market sector of projected Immunotherapy for Neuroblastoma sales for 2023 through 2029. With Immunotherapy for Neuroblastoma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Immunotherapy for Neuroblastoma industry.

This Insight Report provides a comprehensive analysis of the global Immunotherapy for Neuroblastoma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Immunotherapy for Neuroblastoma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Immunotherapy for Neuroblastoma market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immunotherapy for Neuroblastoma and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immunotherapy for Neuroblastoma.

This report presents a comprehensive overview, market shares, and growth opportunities of Immunotherapy for Neuroblastoma market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type

Dinutuximab

Naxitamab

Other

Segmentation by application

Hospital

Clinic

Other

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

United Therapeutics

Y-mAbs Therapeutics

EUSA Pharma

ANI Pharmaceuticals

Baxter Healthcare

Ingenus Pharmaceuticals

Pfizer

Hikma Pharmaceuticals

Teva Pharmaceuticals

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Immunotherapy for Neuroblastoma Market Size 2018-2029
 - 2.1.2 Immunotherapy for Neuroblastoma Market Size CAGR by Region 2018 VS 2022 VS 2029
- 2.2 Immunotherapy for Neuroblastoma Segment by Type
 - 2.2.1 Dinutuximab
 - 2.2.2 Naxitamab
 - 2.2.3 Other
- 2.3 Immunotherapy for Neuroblastoma Market Size by Type
 - 2.3.1 Immunotherapy for Neuroblastoma Market Size CAGR by Type (2018 VS 2022 VS 2029)
 - 2.3.2 Global Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)
- 2.4 Immunotherapy for Neuroblastoma Segment by Application
 - 2.4.1 Hospital
 - 2.4.2 Clinic
 - 2.4.3 Other
- 2.5 Immunotherapy for Neuroblastoma Market Size by Application
 - 2.5.1 Immunotherapy for Neuroblastoma Market Size CAGR by Application (2018 VS 2022 VS 2029)
 - 2.5.2 Global Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)

3 IMMUNOTHERAPY FOR NEUROBLASTOMA MARKET SIZE BY PLAYER

3.1 Immunotherapy for Neuroblastoma Market Size Market Share by Players

3.1.1 Global Immunotherapy for Neuroblastoma Revenue by Players (2018-2023)

3.1.2 Global Immunotherapy for Neuroblastoma Revenue Market Share by Players (2018-2023)

3.2 Global Immunotherapy for Neuroblastoma Key Players Head office and Products Offered

3.3 Market Concentration Rate Analysis

3.3.1 Competition Landscape Analysis

3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)

3.4 New Products and Potential Entrants

3.5 Mergers & Acquisitions, Expansion

4 IMMUNOTHERAPY FOR NEUROBLASTOMA BY REGIONS

4.1 Immunotherapy for Neuroblastoma Market Size by Regions (2018-2023)

4.2 Americas Immunotherapy for Neuroblastoma Market Size Growth (2018-2023)

4.3 APAC Immunotherapy for Neuroblastoma Market Size Growth (2018-2023)

4.4 Europe Immunotherapy for Neuroblastoma Market Size Growth (2018-2023)

4.5 Middle East & Africa Immunotherapy for Neuroblastoma Market Size Growth (2018-2023)

5 AMERICAS

5.1 Americas Immunotherapy for Neuroblastoma Market Size by Country (2018-2023)

5.2 Americas Immunotherapy for Neuroblastoma Market Size by Type (2018-2023)

5.3 Americas Immunotherapy for Neuroblastoma Market Size by Application (2018-2023)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Immunotherapy for Neuroblastoma Market Size by Region (2018-2023)

6.2 APAC Immunotherapy for Neuroblastoma Market Size by Type (2018-2023)

6.3 APAC Immunotherapy for Neuroblastoma Market Size by Application (2018-2023)

6.4 China

- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia

7 EUROPE

- 7.1 Europe Immunotherapy for Neuroblastoma by Country (2018-2023)
- 7.2 Europe Immunotherapy for Neuroblastoma Market Size by Type (2018-2023)
- 7.3 Europe Immunotherapy for Neuroblastoma Market Size by Application (2018-2023)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia

8 MIDDLE EAST & AFRICA

- 8.1 Middle East & Africa Immunotherapy for Neuroblastoma by Region (2018-2023)
- 8.2 Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Type (2018-2023)
- 8.3 Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Application (2018-2023)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

10 GLOBAL IMMUNOTHERAPY FOR NEUROBLASTOMA MARKET FORECAST

- 10.1 Global Immunotherapy for Neuroblastoma Forecast by Regions (2024-2029)

- 10.1.1 Global Immunotherapy for Neuroblastoma Forecast by Regions (2024-2029)
- 10.1.2 Americas Immunotherapy for Neuroblastoma Forecast
- 10.1.3 APAC Immunotherapy for Neuroblastoma Forecast
- 10.1.4 Europe Immunotherapy for Neuroblastoma Forecast
- 10.1.5 Middle East & Africa Immunotherapy for Neuroblastoma Forecast
- 10.2 Americas Immunotherapy for Neuroblastoma Forecast by Country (2024-2029)
 - 10.2.1 United States Immunotherapy for Neuroblastoma Market Forecast
 - 10.2.2 Canada Immunotherapy for Neuroblastoma Market Forecast
 - 10.2.3 Mexico Immunotherapy for Neuroblastoma Market Forecast
 - 10.2.4 Brazil Immunotherapy for Neuroblastoma Market Forecast
- 10.3 APAC Immunotherapy for Neuroblastoma Forecast by Region (2024-2029)
 - 10.3.1 China Immunotherapy for Neuroblastoma Market Forecast
 - 10.3.2 Japan Immunotherapy for Neuroblastoma Market Forecast
 - 10.3.3 Korea Immunotherapy for Neuroblastoma Market Forecast
 - 10.3.4 Southeast Asia Immunotherapy for Neuroblastoma Market Forecast
 - 10.3.5 India Immunotherapy for Neuroblastoma Market Forecast
 - 10.3.6 Australia Immunotherapy for Neuroblastoma Market Forecast
- 10.4 Europe Immunotherapy for Neuroblastoma Forecast by Country (2024-2029)
 - 10.4.1 Germany Immunotherapy for Neuroblastoma Market Forecast
 - 10.4.2 France Immunotherapy for Neuroblastoma Market Forecast
 - 10.4.3 UK Immunotherapy for Neuroblastoma Market Forecast
 - 10.4.4 Italy Immunotherapy for Neuroblastoma Market Forecast
 - 10.4.5 Russia Immunotherapy for Neuroblastoma Market Forecast
- 10.5 Middle East & Africa Immunotherapy for Neuroblastoma Forecast by Region (2024-2029)
 - 10.5.1 Egypt Immunotherapy for Neuroblastoma Market Forecast
 - 10.5.2 South Africa Immunotherapy for Neuroblastoma Market Forecast
 - 10.5.3 Israel Immunotherapy for Neuroblastoma Market Forecast
 - 10.5.4 Turkey Immunotherapy for Neuroblastoma Market Forecast
 - 10.5.5 GCC Countries Immunotherapy for Neuroblastoma Market Forecast
- 10.6 Global Immunotherapy for Neuroblastoma Forecast by Type (2024-2029)
- 10.7 Global Immunotherapy for Neuroblastoma Forecast by Application (2024-2029)

11 KEY PLAYERS ANALYSIS

- 11.1 United Therapeutics
 - 11.1.1 United Therapeutics Company Information
 - 11.1.2 United Therapeutics Immunotherapy for Neuroblastoma Product Offered
 - 11.1.3 United Therapeutics Immunotherapy for Neuroblastoma Revenue, Gross

Margin and Market Share (2018-2023)

11.1.4 United Therapeutics Main Business Overview

11.1.5 United Therapeutics Latest Developments

11.2 Y-mAbs Therapeutics

11.2.1 Y-mAbs Therapeutics Company Information

11.2.2 Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Product Offered

11.2.3 Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Revenue, Gross

Margin and Market Share (2018-2023)

11.2.4 Y-mAbs Therapeutics Main Business Overview

11.2.5 Y-mAbs Therapeutics Latest Developments

11.3 EUSA Pharma

11.3.1 EUSA Pharma Company Information

11.3.2 EUSA Pharma Immunotherapy for Neuroblastoma Product Offered

11.3.3 EUSA Pharma Immunotherapy for Neuroblastoma Revenue, Gross Margin and

Market Share (2018-2023)

11.3.4 EUSA Pharma Main Business Overview

11.3.5 EUSA Pharma Latest Developments

11.4 ANI Pharmaceuticals

11.4.1 ANI Pharmaceuticals Company Information

11.4.2 ANI Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered

11.4.3 ANI Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross

Margin and Market Share (2018-2023)

11.4.4 ANI Pharmaceuticals Main Business Overview

11.4.5 ANI Pharmaceuticals Latest Developments

11.5 Baxter Healthcare

11.5.1 Baxter Healthcare Company Information

11.5.2 Baxter Healthcare Immunotherapy for Neuroblastoma Product Offered

11.5.3 Baxter Healthcare Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)

11.5.4 Baxter Healthcare Main Business Overview

11.5.5 Baxter Healthcare Latest Developments

11.6 Ingenus Pharmaceuticals

11.6.1 Ingenus Pharmaceuticals Company Information

11.6.2 Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered

11.6.3 Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross

Margin and Market Share (2018-2023)

11.6.4 Ingenus Pharmaceuticals Main Business Overview

11.6.5 Ingenus Pharmaceuticals Latest Developments

11.7 Pfizer

- 11.7.1 Pfizer Company Information
- 11.7.2 Pfizer Immunotherapy for Neuroblastoma Product Offered
- 11.7.3 Pfizer Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
- 11.7.4 Pfizer Main Business Overview
- 11.7.5 Pfizer Latest Developments
- 11.8 Hikma Pharmaceuticals
 - 11.8.1 Hikma Pharmaceuticals Company Information
 - 11.8.2 Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
 - 11.8.3 Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.8.4 Hikma Pharmaceuticals Main Business Overview
 - 11.8.5 Hikma Pharmaceuticals Latest Developments
- 11.9 Teva Pharmaceuticals
 - 11.9.1 Teva Pharmaceuticals Company Information
 - 11.9.2 Teva Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
 - 11.9.3 Teva Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
 - 11.9.4 Teva Pharmaceuticals Main Business Overview
 - 11.9.5 Teva Pharmaceuticals Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Immunotherapy for Neuroblastoma Market Size CAGR by Region (2018 VS 2022 VS 2029) & (\$ Millions)

Table 2. Major Players of Dinutuximab

Table 3. Major Players of Naxitamab

Table 4. Major Players of Other

Table 5. Immunotherapy for Neuroblastoma Market Size CAGR by Type (2018 VS 2022 VS 2029) & (\$ Millions)

Table 6. Global Immunotherapy for Neuroblastoma Market Size by Type (2018-2023) & (\$ Millions)

Table 7. Global Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)

Table 8. Immunotherapy for Neuroblastoma Market Size CAGR by Application (2018 VS 2022 VS 2029) & (\$ Millions)

Table 9. Global Immunotherapy for Neuroblastoma Market Size by Application (2018-2023) & (\$ Millions)

Table 10. Global Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)

Table 11. Global Immunotherapy for Neuroblastoma Revenue by Players (2018-2023) & (\$ Millions)

Table 12. Global Immunotherapy for Neuroblastoma Revenue Market Share by Player (2018-2023)

Table 13. Immunotherapy for Neuroblastoma Key Players Head office and Products Offered

Table 14. Immunotherapy for Neuroblastoma Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)

Table 15. New Products and Potential Entrants

Table 16. Mergers & Acquisitions, Expansion

Table 17. Global Immunotherapy for Neuroblastoma Market Size by Regions 2018-2023 & (\$ Millions)

Table 18. Global Immunotherapy for Neuroblastoma Market Size Market Share by Regions (2018-2023)

Table 19. Global Immunotherapy for Neuroblastoma Revenue by Country/Region (2018-2023) & (\$ millions)

Table 20. Global Immunotherapy for Neuroblastoma Revenue Market Share by Country/Region (2018-2023)

Table 21. Americas Immunotherapy for Neuroblastoma Market Size by Country (2018-2023) & (\$ Millions)

Table 22. Americas Immunotherapy for Neuroblastoma Market Size Market Share by Country (2018-2023)

Table 23. Americas Immunotherapy for Neuroblastoma Market Size by Type (2018-2023) & (\$ Millions)

Table 24. Americas Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)

Table 25. Americas Immunotherapy for Neuroblastoma Market Size by Application (2018-2023) & (\$ Millions)

Table 26. Americas Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)

Table 27. APAC Immunotherapy for Neuroblastoma Market Size by Region (2018-2023) & (\$ Millions)

Table 28. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Region (2018-2023)

Table 29. APAC Immunotherapy for Neuroblastoma Market Size by Type (2018-2023) & (\$ Millions)

Table 30. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)

Table 31. APAC Immunotherapy for Neuroblastoma Market Size by Application (2018-2023) & (\$ Millions)

Table 32. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)

Table 33. Europe Immunotherapy for Neuroblastoma Market Size by Country (2018-2023) & (\$ Millions)

Table 34. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Country (2018-2023)

Table 35. Europe Immunotherapy for Neuroblastoma Market Size by Type (2018-2023) & (\$ Millions)

Table 36. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)

Table 37. Europe Immunotherapy for Neuroblastoma Market Size by Application (2018-2023) & (\$ Millions)

Table 38. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)

Table 39. Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Region (2018-2023) & (\$ Millions)

Table 40. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market

Share by Region (2018-2023)

Table 41. Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Type (2018-2023) & (\$ Millions)

Table 42. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)

Table 43. Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Application (2018-2023) & (\$ Millions)

Table 44. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)

Table 45. Key Market Drivers & Growth Opportunities of Immunotherapy for Neuroblastoma

Table 46. Key Market Challenges & Risks of Immunotherapy for Neuroblastoma

Table 47. Key Industry Trends of Immunotherapy for Neuroblastoma

Table 48. Global Immunotherapy for Neuroblastoma Market Size Forecast by Regions (2024-2029) & (\$ Millions)

Table 49. Global Immunotherapy for Neuroblastoma Market Size Market Share Forecast by Regions (2024-2029)

Table 50. Global Immunotherapy for Neuroblastoma Market Size Forecast by Type (2024-2029) & (\$ Millions)

Table 51. Global Immunotherapy for Neuroblastoma Market Size Forecast by Application (2024-2029) & (\$ Millions)

Table 52. United Therapeutics Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors

Table 53. United Therapeutics Immunotherapy for Neuroblastoma Product Offered

Table 54. United Therapeutics Immunotherapy for Neuroblastoma Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 55. United Therapeutics Main Business

Table 56. United Therapeutics Latest Developments

Table 57. Y-mAbs Therapeutics Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors

Table 58. Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Product Offered

Table 59. Y-mAbs Therapeutics Main Business

Table 60. Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 61. Y-mAbs Therapeutics Latest Developments

Table 62. EUSA Pharma Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors

Table 63. EUSA Pharma Immunotherapy for Neuroblastoma Product Offered

Table 64. EUSA Pharma Main Business

Table 65. EUSA Pharma Immunotherapy for Neuroblastoma Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 66. EUSA Pharma Latest Developments

Table 67. ANI Pharmaceuticals Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors

Table 68. ANI Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered

Table 69. ANI Pharmaceuticals Main Business

Table 70. ANI Pharmaceuticals Immunotherapy for Neuroblastoma Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 71. ANI Pharmaceuticals Latest Developments

Table 72. Baxter Healthcare Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors

Table 73. Baxter Healthcare Immunotherapy for Neuroblastoma Product Offered

Table 74. Baxter Healthcare Main Business

Table 75. Baxter Healthcare Immunotherapy for Neuroblastoma Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 76. Baxter Healthcare Latest Developments

Table 77. Ingenus Pharmaceuticals Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors

Table 78. Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered

Table 79. Ingenus Pharmaceuticals Main Business

Table 80. Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 81. Ingenus Pharmaceuticals Latest Developments

Table 82. Pfizer Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors

Table 83. Pfizer Immunotherapy for Neuroblastoma Product Offered

Table 84. Pfizer Main Business

Table 85. Pfizer Immunotherapy for Neuroblastoma Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 86. Pfizer Latest Developments

Table 87. Hikma Pharmaceuticals Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors

Table 88. Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered

Table 89. Hikma Pharmaceuticals Main Business

Table 90. Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 91. Hikma Pharmaceuticals Latest Developments

Table 92. Teva Pharmaceuticals Details, Company Type, Immunotherapy for

Neuroblastoma Area Served and Its Competitors

Table 93. Teva Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered

Table 94. Teva Pharmaceuticals Main Business

Table 95. Teva Pharmaceuticals Immunotherapy for Neuroblastoma Revenue (\$ million), Gross Margin and Market Share (2018-2023)

Table 96. Teva Pharmaceuticals Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Immunotherapy for Neuroblastoma Report Years Considered

Figure 2. Research Objectives

Figure 3. Research Methodology

Figure 4. Research Process and Data Source

Figure 5. Global Immunotherapy for Neuroblastoma Market Size Growth Rate
2018-2029 (\$ Millions)

Figure 6. Immunotherapy for Neuroblastoma Sales by Geographic Region (2018, 2022
& 2029) & (\$ millions)

Figure 7. Immunotherapy for Neuroblastoma Sales Market Share by Country/Region
(2022)

Figure 8. Immunotherapy for Neuroblastoma Sales Market Share by Country/Region
(2018, 2022 & 2029)

Figure 9. Global Immunotherapy for Neuroblastoma Market Size Market Share by Type
in 2022

Figure 10. Immunotherapy for Neuroblastoma in Hospital

Figure 11. Global Immunotherapy for Neuroblastoma Market: Hospital (2018-2023) & (\$
Millions)

Figure 12. Immunotherapy for Neuroblastoma in Clinic

Figure 13. Global Immunotherapy for Neuroblastoma Market: Clinic (2018-2023) & (\$
Millions)

Figure 14. Immunotherapy for Neuroblastoma in Other

Figure 15. Global Immunotherapy for Neuroblastoma Market: Other (2018-2023) & (\$
Millions)

Figure 16. Global Immunotherapy for Neuroblastoma Market Size Market Share by
Application in 2022

Figure 17. Global Immunotherapy for Neuroblastoma Revenue Market Share by Player
in 2022

Figure 18. Global Immunotherapy for Neuroblastoma Market Size Market Share by
Regions (2018-2023)

Figure 19. Americas Immunotherapy for Neuroblastoma Market Size 2018-2023 (\$
Millions)

Figure 20. APAC Immunotherapy for Neuroblastoma Market Size 2018-2023 (\$ Millions)

Figure 21. Europe Immunotherapy for Neuroblastoma Market Size 2018-2023 (\$
Millions)

Figure 22. Middle East & Africa Immunotherapy for Neuroblastoma Market Size

2018-2023 (\$ Millions)

Figure 23. Americas Immunotherapy for Neuroblastoma Value Market Share by Country in 2022

Figure 24. United States Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 (\$ Millions)

Figure 25. Canada Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 (\$ Millions)

Figure 26. Mexico Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 (\$ Millions)

Figure 27. Brazil Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 (\$ Millions)

Figure 28. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Region in 2022

Figure 29. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Type in 2022

Figure 30. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Application in 2022

Figure 31. China Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 (\$ Millions)

Figure 32. Japan Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 (\$ Millions)

Figure 33. Korea Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 (\$ Millions)

Figure 34. Southeast Asia Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 (\$ Millions)

Figure 35. India Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 (\$ Millions)

Figure 36. Australia Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 (\$ Millions)

Figure 37. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Country in 2022

Figure 38. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)

Figure 39. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)

Figure 40. Germany Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 (\$ Millions)

Figure 41. France Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 (\$ Millions)

Figure 42. UK Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 (\$ Millions)

Figure 43. Italy Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 (\$ Millions)

Figure 44. Russia Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 (\$ Millions)

Figure 45. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Region (2018-2023)

Figure 46. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)

Figure 47. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)

Figure 48. Egypt Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 (\$ Millions)

Figure 49. South Africa Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 (\$ Millions)

Figure 50. Israel Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 (\$ Millions)

Figure 51. Turkey Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 (\$ Millions)

Figure 52. GCC Country Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 (\$ Millions)

Figure 53. Americas Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 54. APAC Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 55. Europe Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 56. Middle East & Africa Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 57. United States Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 58. Canada Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 59. Mexico Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 60. Brazil Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 61. China Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 62. Japan Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 63. Korea Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 64. Southeast Asia Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 65. India Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 66. Australia Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 67. Germany Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 68. France Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 69. UK Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 70. Italy Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 71. Russia Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 72. Spain Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 73. Egypt Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 74. South Africa Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 75. Israel Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 76. Turkey Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 77. GCC Countries Immunotherapy for Neuroblastoma Market Size 2024-2029 (\$ Millions)

Figure 78. Global Immunotherapy for Neuroblastoma Market Size Market Share Forecast by Type (2024-2029)

Figure 79. Global Immunotherapy for Neuroblastoma Market Size Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Immunotherapy for Neuroblastoma Market Growth (Status and Outlook)
2023-2029

Product link: <https://marketpublishers.com/r/GEC8E5EF9F48EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GEC8E5EF9F48EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

